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The progressive myoclonic epilepsies (PME) are a heterogeneous group of disorders in which
a speciﬁc diagnosis cannot be made in a subset of patients, despite exhaustive investigation.
C9orf72 repeat expansions are emerging as an important causal factor in several adult-onset
neurodegenerative disorders, in particular frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. An association with PME has not been reported previously.
Objective
To identify the causative mutation in a Belgian family where the proband had genetically
unexplained PME.
Results
We report a 33-year old woman who had epilepsy since the age of 15 and then developed
progressive cognitive deterioration and multifocal myoclonus at the age of 18. The family
history suggested autosomal dominant inheritance of psychiatric disorders, epilepsy, and de-
mentia. Thorough workup for PME including whole exome sequencing did not reveal an
underlying cause, but aC9orf72 repeat expansion was found in our patient and aﬀected relatives.
Brain biopsy conﬁrmed the presence of characteristic p62-positive neuronal cytoplasmic
inclusions.
Conclusion
C9orf72mutation analysis should be considered in patients with PME and psychiatric disorders
or dementia, even when the onset is in late childhood or adolescence.
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The progressive myoclonic epilepsies (PME) are a heteroge-
neous group of neurodegenerative diseases with variable age at
onset and cause, all resulting in a progressive syndrome of
myoclonic jerks and epileptic seizures, often accompanied by
dementia and ataxia.1 There are over 20 established genetic
causes of PMEwith the more common ones being Unverricht-
Lundborg and Lafora body disease due to mutations in CSTB
and EPM2A/EPM2B, respectively, the neuronal ceroid lip-
ofuscinoses (NCL), sialidoses due to neuraminidase de-
ﬁciency, and mitochondrial encephalopathy with ragged red
ﬁbers. A recent large multicenter study could not identify an
underlying cause in 28% of patients with PME.2
C9orf72 hexanucleotide repeat expansions are the main
cause of genetic frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS). Average age at onset is
in the 6th decade, with a range between 27 and 83 years.3,4
Since their ﬁrst description in 2011,5–7 the clinical pheno-
type associated with these mutations has expanded beyond
the FTD/ALS spectrum. Parkinsonism and psychiatric
features are well established now, and hyperkinetic or cer-
ebellar movement disorders have been described.8,9 Seiz-
ures are rarely described10,11 and PME has not been
reported.
We describe a patient with PME and a C9orf72 repeat ex-
pansion, with ﬁrst symptoms appearing at the age of 15. Onset
in the pediatric years and the phenotype of PME broadens the
C9orf72-related phenotypic spectrum and could provide an
opportunity for patients with PME for whom no underlying
cause has been detected.
Case report
A 33-year-old woman was referred to the neurology de-
partment of a tertiary care hospital in Belgium because of
progressive cognitive decline and speech diﬃculties. She had
had epilepsy with generalized tonic-clonic seizures and
myoclonic jerks since the age of 15 but was seizure-free for
several years under treatment with valproic acid, levetir-
acetam, and clobazam. She was reportedly well before the age
of 15, with average school performance. She lived with her
partner and could perform all activities of daily life in-
dependently. Despite attempting higher education at the age
of 18, she did not succeed and was currently employed in
a sheltered workshop.
On clinical examination, the patient was alert and co-
operative, and was well-oriented in time and space. She had
a score of 24/30 on theMini-Mental State Examination, with
striking deﬁcits in attention and upon executing more
complex commands. Vital signs were normal. Neurologic
examination of the cranial nerves was normal, as were fun-
duscopy, sensory examination, strength, and reﬂexes in all 4
limbs, with absence of clear pyramidal and frontal signs. Gait
was slightly broad-based. Small-amplitude myoclonic jerks
were noted in the arms, legs, and ﬁngers, which interfered
with cerebellar testing, but there was no ataxia. She did
not have tremor; muscle tone was normal. Speech was slow,
with multifocal facial myoclonus both at rest and during
speaking, and she displayed signs of neurogenic stuttering.
Speech-induced dystonic facial contractions were in-
frequently seen.
Neuropsychological testing 3 months after initial evalua-
tion showed mostly deﬁcits in attention and executive
functions and to a lesser extent in verbal memory (table
e-1, http://links.lww.com/WNL/A174). EEG repeatedly
showed a moderate increase in slow activity in the theta
and delta range, as well as occasional low-amplitude,
generalized spike-wave discharges with central maximum,
without clear photosensitivity (ﬁgure 1B).
The family history revealed several patients with adult-
onset psychiatric or neurodegenerative disorders (ﬁgure
1A); more details are provided in the supplementary
text (http://links.lww.com/WNL/A176). The mother of
the proband (II-2) had been hospitalized at age 47 be-
cause of anxiety and depression but subsequently de-
veloped epilepsy at age 48 and a progressive cognitive
decline compatible with FTD, which led to her death at
age 56. A maternal aunt (II-4) had depression and mem-
ory problems. Neuropsychological testing suggested
a possible FTD with onset in her mid-50s (data not
shown).
Adult-onset autosomal dominant PME was diagnosed and
further examinations were focused on elucidating the un-
derlying cause. Ophthalmologic examination was normal.
Routine blood analysis (table e-2, http://links.lww.com/
WNL/A174) did not reveal abnormalities, nor did testing of
CSF including dementia biomarkers (table e-3, http://links.
lww.com/WNL/A174). MRI of the brain revealed general-
ized cerebral and cerebellar atrophy, mostly in the bilateral
parietal lobes (ﬁgure 1C) with concordant relative hypo-
metabolism on FDG-PET imaging. Skin and muscle
biopsy were normal as were mitochondrial enzyme activi-
ties in muscle. Genetic testing for autosomal dominant spi-
nocerebellar ataxias (SCA1-2-3-6-7-17), dentatorubral-
Glossary
ALS = amyotrophic lateral sclerosis; ANCL = adult neuronal ceroid lipofuscinosis; EM = electron microscopy; FTD =
frontotemporal dementia; NCL = neuronal ceroid lipofuscinoses; PME = progressive myoclonic epilepsies; WES = whole
exome sequencing.
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pallidoluysian atrophy, Huntington disease, and familial
Alzheimer disease (PSEN1-2, APP) was normal. Microarray-
based comparative genomic hybridization did not reveal
pathologic copy number variations. Whole exome sequenc-
ing (WES) of the patient and her maternal aunt was per-
formed in the context of the ANCL Gene Discovery
Consortium.12 The WES dataset was ﬁltered for variants in
PME causative genes, namely KCNC1, CERS1, PRICKLE1,
EPM2A, GOSR2, KCTD7, LMNB2, NHLRC1, PRDM8,
CSTB, SCARB2, and DNAJC5,13 having a minor allele fre-
quency <5% in the ExAC database. Using this approach, we
did not detect any candidate variants in the proband. Ad-
ditional searching for genetic alterations in a wider spectrum
of epilepsy genes14 did not reveal any potential candidate
mutations.
Electron microscopy (EM) examination of a brain biopsy
from the patient’s right parietal lobe at age 34 showed some
nonspeciﬁc increase in lipopigment (ﬁgure 2A), but no evi-
dence of Lafora bodies or material diagnostic for NCL. EM
analysis of the muscle biopsy of the maternal aunt (II-4) was
more ambiguous and suggested presence of pathologic stor-
age material in the form of lipopigment with occasional ﬁn-
gerprints (ﬁgure 2, B and C), although insuﬃcient to establish
a deﬁnite diagnosis of adult neuronal ceroid lipofuscinosis
(ANCL) or Kufs disease. Subsequent expert review of the
Figure 1 Pedigree, neurophysiology, and brain imaging of the proband
(A) Pedigree of the affected family.
Shaded symbols denote affected family
members; the proband is indicated
with an arrow. Confirmed heterozy-
gous C9orf72 repeat expansions are
shown as +/−; obligate carrier status is
indicated as (+/−). (B) Representative
EEG of the proband with a bilateral,
synchronous epileptiform spike-wave
discharge highlighted in gray. (C) Axial
fluid-attenuated inversion recovery
brain MRI of the proband demon-
strates bilateral parietal lobe atrophy.
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biopsy ﬁndings within the same Consortium excluded the
diagnosis of ANCL.
Next we tested for C9orf72 repeat expansion, which was positive
in both our patient and the aﬀected aunt, as well as in 2 distant
family members (II-6 and II-8) (ﬁgure 1A). Short-repeat PCR3
excluded a repeat size of less than 80 bp in the proband and her
aunt. Further analysis of the brain biopsy with light microscopy
examination showed clear neuronal cytoplasmic inclusions that
stained positive for p62, but were negative for ubiquitin, TDP-43,
and its hyperphosphorylated form (ﬁgure 2, D and E). Auto-
ﬂuorescence was slightly increased and ANCL-related staining
for SCMAS, CathD, and LAMP2 were negative (ﬁgure e-1,
http://links.lww.com/WNL/A175). Additional staining for
amyloid, tau, FUS, and α-synuclein did not reveal pathologic
changes (data not shown).
Discussion
We present a patient with PME and describe a remarkable
association between this clinical syndrome and C9orf72 repeat
expansions. This constitutes an important ﬁnding for patients
with PME of undetermined cause,2 in particular because this
type of intronic mutation cannot be identiﬁed throughWES, as
was the case in our patient. C9orf72 repeat expansions can be
found in about 0.159–0.2%15 of healthy individuals, but the
absence of known PME-related defects in the WES data, and
the segregation of the repeat expansion in the family, support
a direct pathogenic role for the C9orf72 repeat expansion in the
PME phenotype of our patient.
Because of the autosomal dominant inheritance of adult-onset
neuropsychiatric symptoms in family members, we focused
our initial workup on the possibility of ANCL or Kufs disease
causing PME in our patient. EM analysis of muscle tissue from
the patient’s maternal aunt also suggested an increase in
pathologic lipofuscin-type deposits, but a deﬁnite diagnosis of
ANCL could not be conﬁrmed by the pathologists of the
ANCL Consortium.12 Mining publicly accessible databases
with available data on C9orf72 status9,16 did not reveal addi-
tional cases with symptoms suggestive of PME. Analysis of the
patients with ANCL with autosomal dominant PME but
without genetic diagnosis from the ANCL Consortium did
not reveal other C9orf72 repeat expansions (n = 5). Larger
cohorts of patients with PME have not been tested.
This report supports the novel and emerging concept of
disease anticipation in families segregating a C9orf72 repeat
expansion.17 Symptoms associated with C9orf72 repeat
Figure 2 Electron microscopy and immunohistochemistry
(A) Electronmicroscopy of the brain cortex of patient III-2 (proband) shows intraneuronal classical lipofuscin. (B, C) Electronmicroscopy of the skeletal muscle
biopsy of patient II-4 demonstrates lipofuscin-like inclusions with fingerprints. (D.a, D.b) p62 staining in the brain cortex of patient III-2, with p62 positive
cytoplasmic inclusions of different shape in some neurons and occasionally in glial cells. (E) Phospho-TDP-43 negative staining in the brain cortex. Magni-
fications ×27,000 (A), ×67,500 (B), ×107,500 (C), ×4 (D.a, E), and ×20 (D.b).
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expansions typically manifest after the 4th decade,5 as illus-
trated by the proband’s mother (II-2, onset around 47 years)
and maternal aunt (II-4, onset around 55 years). Our patient
had her ﬁrst epileptic seizure more than 30 years earlier at age
15 and quickly thereafter developed progressive cognitive
decline. Short-repeat PCR did not reveal the presence of short
expansions in the proband or maternal aunt, and it is not yet
possible to determine the exact length of longer repeat
expansions. Although many factors may contribute to the
clinical variation, one can speculate that meiotic repeat in-
stability in the mother has resulted in a further expansion of
the hexanucleotide repeat in the proband, resulting in the very
early onset and atypical PME presentation.
It is intriguing to note that for a number of mid- to late-life
inherited neurodegenerative diseases like Alzheimer disease,18
Huntington disease,19 neuroserpinopathy,20 and dentatorubral-
pallidoluysian atrophy,21 classically presenting as dementias, the
presentation can be of a PMEwhen familymembers have an early
onset. C9orf72 repeat expansion can now be added to this list.
Our description of PME due to C9orf72 repeat expansion
expands the phenotypic spectrum associated with this intriguing
noncoding hexanucleotide repeat expansion. Testing for this
mutation should be considered in the workup of patients with
PME, even when onset is in late childhood or adolescence.
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What is the pathogenic mutation in the family of a Belgian
woman with genetically unexplained progressive myoclonic
epilepsy (PME)?
Summary answer
A C9orf72 repeat expansion was found in the proband and
aﬀected relatives.
What is known and what this article adds
C9orf72 repeat expansions have been identiﬁed as causal
factors in various neurodegenerative diseases. This case report
provides evidence that C9orf72 repeat expansions should be
considered as potential causal factors in PME.
Participants and setting
This case report concerns a 33-year-old Belgian woman who
developed epilepsy at 15 years of age and exhibited pro-
gressive cognitive deterioration and multifocal myoclonus
since 18 years of age. She was referred to a tertiary care
hospital’s neurology department.
Design, size, and duration
The woman’s clinical presentation, clinical history, and family
disease history were noted. She underwent various neuro-
physiologic examinations. Genetic tests and whole exome
sequencing were performed to search for potentially patho-
logic mutations, and a brain biopsy sample was collected.
Tests for C9orf72 repeat expansions were also conducted.
Main results and the role of chance
The patient had cognitive and speech deﬁcits and experienced
small-amplitude myoclonic jerks. Her family history revealed
several relatives with adult-onset psychiatric or neurodegen-
erative disorders. The patient was diagnosed with adult-onset
autosomal dominant PME. Genetic testing and whole exome
sequencing detected no known PME-causing mutations.
Tests for C9orf72 repeat expansions were positive in the pa-
tient, an aunt with depression and memory problems, and 2
distant family members. The brain biopsy sample contained
p62-positive neuronal cytoplasmic inclusions that are associ-
ated with C9orf72 repeat expansions.
Bias, confounding, and other reasons
for caution
Mining of genetic databases that include data on C9orf72
repeat expansions did not identify any patients with symp-
toms suggestive of PME, and testing 5 additional patients
from a database of patients with adult neuronal ceroid lip-
ofuscinosis and PME did not identify C9orf72 repeat
expansions.
Generalizability to other populations
This case report concerned a single patient and her family;
hence, the results may not be widely generalizable.
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